OMONTYS PRESERVATIVE FREE Drug Patent Profile

When do Omontys Preservative Free patents expire, and what generic alternatives are available?

Omontys Preservative Free is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are two patents protecting this drug.

This drug has twenty-seven patent family members in eighteen countries.

The generic ingredient in OMONTYS PRESERVATIVE FREE is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.

DrugPatentWatch^® Generic Entry Outlook for Omontys Preservative Free

Omontys Preservative Free was eligible for patent challenges on March 27, 2016.

Indicators of Generic Entry

Summary for OMONTYS PRESERVATIVE FREE

International Patents:	27
US Patents:	2
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for OMONTYS PRESERVATIVE FREE

OMONTYS PRESERVATIVE FREE is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	OMONTYS PRESERVATIVE FREE	peginesatide acetate	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	202799-001	Mar 27, 2012		DISCN	No	No
Takeda Pharms Usa	OMONTYS PRESERVATIVE FREE	peginesatide acetate	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	202799-004	Mar 27, 2012		DISCN	No	No
Takeda Pharms Usa	OMONTYS PRESERVATIVE FREE	peginesatide acetate	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	202799-002	Mar 27, 2012		DISCN	No	No
Takeda Pharms Usa	OMONTYS PRESERVATIVE FREE	peginesatide acetate	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	202799-006	Mar 27, 2012		DISCN	No	No
Takeda Pharms Usa	OMONTYS PRESERVATIVE FREE	peginesatide acetate	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	202799-004	Mar 27, 2012		DISCN	No	No
Takeda Pharms Usa	OMONTYS PRESERVATIVE FREE	peginesatide acetate	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	202799-001	Mar 27, 2012		DISCN	No	No

International Patents for OMONTYS PRESERVATIVE FREE

See the table below for patents covering OMONTYS PRESERVATIVE FREE around the world.

Country	Patent Number	Title	Estimated Expiration
Norway	20055852
Japan	2007500218
Japan	4949844
World Intellectual Property Organization (WIPO)	2009025958
Australia	2004238870	Novel peptides that bind to the erythropoietin receptor
Portugal	1629007

OMONTYS Preservative-Free: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Executive Summary

OMONTYS Preservative-Free (rarectalized: Peginesatide), developed by Santarus (acquired by Salix Pharmaceuticals in 2015), is a recombinant erythropoiesis-stimulating agent (ESA) designed primarily for anemia management in dialysis-dependent chronic kidney disease (CKD). Although launched in select markets, it encountered regulatory and market challenges leading to limited commercial success. This report evaluates the investment viability, market environment, and projected financial trajectory of OMONTYS Preservative-Free, with emphasis on key market drivers, competitive landscape, regulatory considerations, and commercialization prospects.

---

1. Investment Overview

1.1 Product Profile and Regulatory Status

Attribute	Details
Generic Name	Peginesatide
Formulation	Preservative-Free, Intravenous and Subcutaneous
Indication	Anemia in CKD Patients on Dialysis
Regulatory Status (USA)	Approved 2012 by FDA; withdrawn 2013 due to safety concerns
Regulatory Status (Europe)	Not approved; withdrawn from consideration
Current Market Status	Withdrawn/restricted; limited to research use in some instances

Key point: OMONTYS faced major safety issues (notably severe allergic reactions), culminating in market withdrawal, severely hampering investment returns and future adoption potential.

1.2 Market Entry Timeline and Commercial Impact

Year	Event	Market Effect

| 2012 | FDA approval (USA) | Initial market entry potential | | 2013 | Market withdrawal; safety concerns | Major setback, limited commercial viability | | 2015 | Acquisition by Salix Pharmaceuticals | Integration but limited revival plans | | 2020+ | No current commercial launches | Market practically inactive |

Investment implication: Historically high risk; limited near-term revenue potential due to safety withdrawals, emphasizing the importance of regulatory validation in future development.

---

2. Market Dynamics

2.1 Market Size and Growth Potential

Region	CKD Dialysis Population (Millions)	Estimated ESA Market Size (USD billions, 2022)	CAGR (2018-2023)
North America	0.7	$1.2	4.5%
Europe	0.5	$0.8	4.0%
Asia-Pacific	1.2	$0.9	6.2%
Total	2.4	$2.9	~4.8%

Source: Market Research Future (2022)

The demand for ESAs like OMONTYS is driven primarily by the prevalence of CKD and dialysis dependence, projected to increase due to aging populations and diabetes prevalence.

2.2 Competitive Landscape

Competitors	Key Products	Formulation	Market Share	Safety Profile	Pricing (USD per dose)
Epogen (Amgen)	Epoetin alfa	Preserved	~60%	Solid, but risks of hypertension, thromboembolic events	150-200
Aranesp (Amgen)	Darbepoetin alfa	Preserved	~20%	Improved dosing, similar safety concerns	180-220
Mircera (Roche)	Methoxy polyethylene glycol-epoetin beta	Preserved	~10%	Similar safety profile	200-250
OMONTYS	Peginesatide	Preservative-Free	Limited	Withdrawn due to safety	N/A

Observation: Despite efficacy, safety issues hamper OMONTYS's competitive position, underscoring the necessity for safer formulations or indications.

2.3 Market Barriers and Opportunities

Barriers	Opportunities
Safety recalls and withdrawals	Development of improved formulations with better safety margins
Established incumbents with strong market presence	Niche targeting or combination therapies
Regulatory hurdles	Early engagement with regulatory authorities; focus on safety validation

---

3. Financial Trajectory Analysis

3.1 Revenue and Sales Projections

Scenario	Year	Estimated Sales (USD millions)	Assumptions
Conservative	2023	Minimal (USD 0-5 million)	Post-withdrawal, limited research use
Moderate	2025	USD 20-50 million	Niche use; improved safety profile; partnership efforts
Optimistic	2030	USD 100+ million	Regained market share with safety improvements; global expansion

Note: Current sales are negligible; recovery is contingent on safety reaffirmation, regulatory approval resumption, and market acceptance.

3.2 R&D and Regulatory Investment Estimates

Item	Estimated Cost (USD millions)	Timeline	Description
Phase I/II Trials	50-100	2023-2025	Focused on safety and efficacy improvements
Regulatory Filing	20-40	2025	Based on successful trial outcomes
Post-approval Monitoring	10-20 annually	2026+	Safety surveillance and pharmacovigilance

Implication: High investment thresholds with uncertain outcomes; careful assessment needed before funding.

3.3 Profitability Outlook

Indicator	2023-2025	2026-2030
Gross Margin	30-50%	50-65% (with safety)
Break-even Point	2024-2026	2025-2027
Return on Investment	Low to Negative (short-term)	Potentially positive with successful safety profile

---

4. Comparative Assessment: Future Outlook

Aspect	OMONTYS (Preservative-Free)	Competing ESAs	Innovative Alternatives
Market Penetration	Limited post-withdrawal	High	Emerging biotechs with novel mechanisms
Safety Profile	Compromised (withdrawn)	Proven (though risks exist)	Potential for safer biologics
Manufacturing Costs	High (complex formulation)	Lower	Variable, depends on technology
Pricing Strategy	Premium for safety	Competitive	Disruptive, value-based

---

5. Regulatory and Policy Considerations

• FDA: Risk-based approaches post-withdrawal; rigorous pharmacovigilance mandated.
• EMA: Similar licensing hurdles; emphasis on safety data.
• Orphan Designations: Limited, due to widespread CKD prevalence.
• Reimbursement: Tied to safety and efficacy; reimbursement prospects may improve with safety validation.

---

6. Recommendations for Stakeholders

Stakeholder	Recommendations
Investors	Prioritize products with verified safety profiles; assess pipeline potential post-market withdrawal.
Biotech Developers	Focus on safety enhancements, novel delivery systems, or indications.
Regulatory Agencies	Emphasize early safety data, facilitate adaptive pathways for improved formulations.
Healthcare Providers	Exercise caution; rely on approved, validated ESAs.

---

Conclusion

OMONTYS Preservative-Free embodied innovative efforts to mitigate adverse events linked to preservative components. However, safety issues led to market withdrawal, significantly dampening its investment appeal. Future opportunities hinge on developing safer formulations, demonstrating clear safety benefits, and securing regulatory approval. The commercial landscape remains competitive with dominant incumbent therapies, but emerging biosimilars and novel biologics may alter market dynamics, offering new avenues for investment.

---

Key Takeaways

• Market Viability: Currently limited; recovery relies on safety enhancements and regulatory clearance.
• Investment Risk: High due to past withdrawals; robust safety data are essential.
• Market Drivers: Increasing CKD prevalence, demand for safer ESAs.
• Competitive Environment: Dominated by established biologics; niche markets or innovation are necessary for growth.
• Regulatory Pathways: Stringent, safety-focused; early engagement essential for success.

---

Frequently Asked Questions (FAQs)

Q1: Why was OMONTYS Preservative-Free withdrawn from the market?
A: The FDA withdrew OMONTYS in 2013 following reports of severe allergic reactions, including anaphylaxis, raising safety concerns that could not be mitigated with current data.

Q2: Is there a potential for reintroducing OMONTYS with a safer profile?
A: Reintroduction depends on demonstrating safety through revised formulations or alternative delivery systems, requiring significant R&D investment and regulatory approval.

Q3: How does the safety profile of OMONTYS compare to competitors?
A: OMONTYS' safety concerns led to its market removal; competitors like Epogen and Aranesp have established safety profiles, though risks persist, emphasizing the need for ongoing pharmacovigilance.

Q4: What are the main market opportunities for preservative-free or safer ESAs?
A: Targeted niche indications, improving safety profiles through innovative formulations, and expanding into underserved markets such as emerging economies.

Q5: What should investors consider before funding RESEARCH into OMONTYS or similar biologics?
A: Regulatory hurdles, safety profiles, clinical efficacy data, manufacturing complexities, and competitive positioning within the evolving CKD treatment landscape.

---

References

[1] MarketWatch, "Global Erythropoiesis Stimulating Agent Market," 2022.
[2] U.S. Food and Drug Administration, "Withdrawal of OMONTYS (peginesatide)," 2013.
[3] Market Research Future, "CKD & ESRD Market Analysis," 2022.
[4] Salix Pharmaceuticals, "Corporate Documents," 2015.
[5] European Medicines Agency, "Assessment Reports," 2014.